Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F18 Fluciclovine PET MR for LITT Response Assessment
NCT05054400Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2020
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Accuracy of F18 Fluciclovine PET MR for LITT treatment response assessment at 1 year. Planned start Feb 2020; status: withdrawn.
Beyond the preview
Go deeper on NCT05054400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054400.